本文已被：浏览 127次 下载 86次
投稿时间：2024-12-03 网络发布日期：2025-12-25
投稿时间：2024-12-03 网络发布日期：2025-12-25
中文摘要: 目的 探讨托拉塞米联合沙库巴曲缬沙坦在治疗心肾综合征（CRS）中的应用及对患者炎症水平、凝血功能和心肾功能的影响。方法 选择2021年11月至2023年11月开滦总医院收治的110例CRS患者作为研究对象，采用信封法随机分为对照组和研究组，每组均55例。对照组采用托拉塞米治疗，研究组在对照组基础上联合沙库巴曲缬沙坦治疗。比较两组的疗效。对比两组治疗后的炎症因子［白细胞介素-18（IL-18）、超敏C反应蛋白（hs-CRP）］、凝血功能［纤维蛋白原（FBG）、凝血酶时间（TT）、凝血酶原时间（PT）以及活化部分凝血活酶时间（APTT）］、心功能［肌红蛋白、心肌肌钙蛋白I（cTnI）以及氨基末端脑利尿钠肽前体（NT-ProBNP）］、肾功能（血尿素氮、血肌酐以及24h尿蛋白定量）等的差异。结果 研究组总有效率高于对照组（92.73%vs78.18%，χ2=4.681，P<0.05）。研究组治疗后hs-CRP、IL-18、FBG水平低于对照组（P<0.05），TT、PT、APTT高于对照组（P<0.05），血清肌红蛋白、cTnI、NT-proBNP水平低于对照组（P<0.05），血尿素氮、血肌酐、24h尿蛋白定量水平均低于对照组（P<0.05）。结论 托拉塞米联合沙库巴曲缬沙坦在CRS患者治疗中展现出显著疗效，能够有效降低患者炎症因子水平和改善凝血功能，在改善心肾功能方面具有积极的促进作用。
Abstract:Objective To investigate the application of torasemide combined with sacubitril valsartan in the treatment of cardiorenal syndrome (CRS) and its effects on patients' inflammatory levels, coagulation function, as well as cardiac and renal function. Methods A total of 110 CRS patients admitted to the Kailuan General Hospital, from November 2021 to November 2023, were selected as study objects. The patients were randomly divided into a control group and a study group using the envelope method, of 55 patients in each group. The control group received torasemide, while the study group received combined treatment of torasemide and sacubitril valsartan. The efficacy of the two groups was compared. The differences in inflammatory factors [ interleukin-18 ( IL-18), high-sensitivity C-reactive protein ( hs-CRP)], coagulation function [fibrinogen (FBG), thrombin time (TT), prothrombin time (PT), and activated partial thromboplastin time (APTT)], cardiac function [myoglobin, cardiac troponin I (cTnI), and N-terminal pro- brain natriuretic peptide (NT-proBNP)], and renal function (blood urea nitrogen, serum creatinine, and 24-hour urinary protein quantification) were compared between the two groups after treatment. Results The total effective rate in the study group was higher than that in the control group (92.73% vs 78.18%, χ2=4.681, P<0.05). After treatment, the levels of hs-CRP, IL-18, and FBG in the study group were lower than those in the control group (P<0.05). The levels of TT, PT, and APTT in the study group were higher than those in the control group (P<0.05). The levels of serum myoglobin, cTnI, and NT-proBNP in the study group were lower than those in the control group (P<0.05). The levels of blood urea nitrogen, serum creatinine, and 24-hour urinary protein quantification in the study group were lower than those in the control group (P<0.05). Conclusion Torasemide combined with sacubitril valsartan has shown significant efficacy in the treatment of CRS patients. It can effectively reduce the levels of inflammatory factors and improve coagulation function, playing a positive role in enhancing both cardiac and renal function.
keywords: Torasemide Sacubitril valsartan Cardiorenal syndrome Coagulation function Urinary protein quantification Troponin Inflammatory factor
文章编号： 中图分类号：R541.6 R692 文献标志码：A
基金项目:河北省医学科学研究课题计划项目（20201286）
附件
引用文本：
戚秀娟,张俊录.托拉塞米联合沙库巴曲缬沙坦治疗心肾综合征[J].中国临床研究,2025,38(12):1898-1902.
戚秀娟,张俊录.托拉塞米联合沙库巴曲缬沙坦治疗心肾综合征[J].中国临床研究,2025,38(12):1898-1902.